Safety and efficacy constitute the major criteria governing regulatory approval of any new
drug. The best method to maximize safety and efficacy is to deliver a proven therapeutic …

With almost 20 million new cases per year, cancer constitutes one of the most important
challenges for public health systems. Unlike traditional chemotherapy, targeted anti-cancer …

DNA materials have emerged as potential nanocarriers for targeted cancer therapy to
precisely deliver cargos with specific purposes. The short half‐life and low bioavailability of …

Human epidermal growth factor receptor 2 (HER2) regulates cell mitosis, proliferation, and
apoptosis. Trastuzumab is a HER2-targeted monoclonal antibody (mAB), which can prolong …

Antisense oligonucleotides (ASOs) are promising therapeutics for treating various
neurological disorders. However, ASOs are unable to readily cross the mammalian blood …

DNA nanorobots have emerged as new tools for nanomedicine with the potential to
ameliorate the delivery and anticancer efficacy of various drugs. DNA nanostructures have …

The ability of cells to manage consequences of exogenous proteotoxicity is key to cellular
homeostasis. While a plethora of well-characterised machinery aids intracellular …

Synergistic immunotherapy of immune checkpoint blockade (ICB) and immunogenic cell
death (ICD) has shown remarkable therapeutic efficacy in various cancers. However …

Autoimmune diseases are a group of serious immune system disorders that are usually
idiopathic and persistent. Currently, autoimmune diseases are often diagnosed after obvious …

Immune checkpoint blockade (ICB) has shown remarkable therapeutic efficacy in a variety of
cancers. However, patients exhibit unexpectedly low response rates to ICB therapy owing to …